Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 742 matching trials from the live ClinicalTrials.gov search.
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine

NCT05738213
Conditions
Migraine
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) response, PedMIDAS (Pediatric Migraine Disability Assessment), Hormonal assessment, Pubertal status
Device · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
11 Years to 15 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Migraine
Interventions
Stimulation of the Occipital Nerves
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
4
States / cities
Newington, New Hampshire • New York, New York • Cincinnati, Ohio + 1 more
Conditions
Pregnancy, Migraine, Headache, Postpartum, Depression, Anxiety
Interventions
external Trigeminal Nerve Stimulation
Device
Lead sponsor
Cefaly Technology
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Darien, Connecticut
Conditions
Migraine
Interventions
MTX101, Placebo
Drug
Lead sponsor
Manistee Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
7
States / cities
La Jolla, California • Santa Monica, California • Miami, Florida + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

Transnasal Therapy for Acute Migraine Attack

NCT04129567
Conditions
Migraine Disorders
Interventions
Humidified oxygen, Dry oxygen, Humidified air, Dry air
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Occipital Neuralgia, Cervicogenic Headache, Migraine Without Aura
Interventions
Ultrasound Guided Greater Occipital Nerve Block at C2, Landmark-Based Greater Occipital Nerve Block
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Migraine
Interventions
Erenumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Migraine
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Newport Beach, California • Stamford, Connecticut + 5 more
Not listed Not applicable Interventional

AVPI Migraine Study

NCT05537818
Conditions
Migraine
Interventions
AVPI Device
Device
Lead sponsor
Nocira, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Saint Charles, Missouri • Springfield, Missouri
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

NCT02792517
Conditions
Headache, Migraine
Interventions
Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
4
States / cities
Anaheim, California • Cypress, California • Dallas, Texas + 1 more
Completed Phase 2 Interventional Results available

A Multicenter Assessment of ALD403 in Chronic Migraine

NCT02275117
Conditions
Migraine Disorders
Interventions
ALD403, Placebo
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
82
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Not listed Not applicable Interventional Accepts healthy volunteers

Migraine and Recurrent Abdominal Pain in Children

NCT00060619
Conditions
Migraine, Abdominal Pain
Interventions
thermal biofeedback, relaxation training, cognitive coping skills, parent education
Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Migraine Disorders
Interventions
sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
49
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
Conditions
Chronic Migraine, Headache
Interventions
Combination of Botox + CGRPmAb (Fremanezumab 225mg/1.5mL)
Drug
Lead sponsor
Chicago Headache Center & Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 2 Interventional Results available

Staccato Loxapine in Migraine (Out Patient)

NCT00825500
Conditions
Migraine Headache
Interventions
Inhaled Placebo, Inhaled Loxapine 1.25 mg, Inhaled Loxapine 2.5 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Springfield, Missouri • Mount Vernon, New York • East Providence, Rhode Island
Conditions
Episodic Migraine
Interventions
Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
113
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
Conditions
Refractory Migraine
Interventions
Botox, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Migraine
Interventions
Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Results available

Efficacy of Erenumab on Functional Impact of Migraine

NCT04465357
Conditions
Migraine
Interventions
Erenumab-Aooe 140 MG/ML [Aimovig]
Drug
Lead sponsor
Merle Diamond
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • City of Saint Peters, Missouri • Springfield, Missouri
Recruiting No phase listed Observational Accepts healthy volunteers

Aimovig Pregnancy Exposure Registry

NCT06150781
Conditions
Migraine
Interventions
erenumab-aooe
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Results available

Evaluation of a Novel Device for Treatment of Migraine Headache

NCT03361423
Conditions
Migraine Without Aura, Migraine With Aura
Interventions
Nerivio Migra-1 active device, Nerivio Migra-1 Sham device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Hartford, Connecticut • Springfield, Missouri • St Louis, Missouri + 4 more
Conditions
Migraine Headache
Interventions
Placebo, Zolmitriptan
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 17 Years
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
46
States / cities
Phoenix, Arizona • Fresno, California • Fullerton, California + 43 more
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

Pain Biomarker Study

NCT03511846
Conditions
Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Hemicrania Continua, Paroxysmal Hemicrania, SUNCT, Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing
Interventions
Oral capsaicin, Topical capsaicin, Intranasal capsaicin, Cold Water Irrigation, Medical Air, Low Flow Oxygen, High Flow Oxygen
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas